MedTrace Logo

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

NCT04761601 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-03-13

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-01-097 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

UCT-01-097

Orally available kinase inhibitor

DRUG

Gemcitabine

Gemcitabine injection for intravenous use.

DRUG

Paclitaxel

Paclitaxel protein-bound particles for injectable suspension (albumin-bound).

Sponsors & Collaborators

  • 1200 Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • Stephen Letrent, PharmD, PhD · 1200 Pharma, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2024-02-19
Completion
2024-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04761601 on ClinicalTrials.gov